Littérature scientifique sur le sujet « Stambomycine »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Stambomycine ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Stambomycine"
Wang, Yongchen, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Gregory L. Challis et Edward A. Anderson. « Synthesis of the C50 diastereomers of the C33–C51 fragment of stambomycin D ». Organic Chemistry Frontiers 9, no 2 (2022) : 445–49. http://dx.doi.org/10.1039/d1qo01635k.
Texte intégralSong, Lijiang, Luisa Laureti, Christophe Corre, Pierre Leblond, Bertrand Aigle et Gregory L. Challis. « Cytochrome P450-mediated hydroxylation is required for polyketide macrolactonization in stambomycin biosynthesis ». Journal of Antibiotics 67, no 1 (13 novembre 2013) : 71–76. http://dx.doi.org/10.1038/ja.2013.119.
Texte intégralSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle et Kira J. Weissman. « Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins ». Nature Communications 13, no 1 (26 janvier 2022). http://dx.doi.org/10.1038/s41467-022-27955-z.
Texte intégralSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle et Kira J. Weissman. « Author Correction : Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins ». Nature Communications 13, no 1 (6 octobre 2022). http://dx.doi.org/10.1038/s41467-022-33524-1.
Texte intégralLim, Jieyan, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Minh Tran, Alice Bernasconi, Araceli Blanco, Lijiang Song, Gregory L. Challis et Edward A. Anderson. « Synthesis of the C1–C27 Fragment of Stambomycin D Validates Modular Polyketide Synthase-Based Stereochemical Assignments ». Organic Letters, 8 septembre 2021. http://dx.doi.org/10.1021/acs.orglett.1c02650.
Texte intégralThèses sur le sujet "Stambomycine"
Su, Li. « Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches ». Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Texte intégralThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation